SCP
GILD icon

Silverleafe Capital Partners’s Gilead Sciences GILD Stock Holding History

Silverleafe Capital Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-34,436
Closed -$2.24M – 70
2019
Q1 		$2.24M Buy
34,436
+22,348
+185% +$1.49M 1.33% 22
2018
Q4 		$756K Buy
12,088
+7,369
+156% +$515K 0.52% 31
2018
Q3 		$364K Buy
4,719
+701
+17% +$52.9K 0.22% 39
2018
Q2 		$285K Buy
+4,018
New +$284K 0.18% 45

Other funds holding GILD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AAMU
Amundi Asset Management US Boston, Massachusetts $131B AUM 73.57% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Silverleafe Capital Partners's GILD Position: Q2 2019 in Review

Silverleafe Capital Partners sold out of Gilead Sciences (GILD) in Q2 2019, closing a stake of 34,436 shares — an estimated $2.24M sold.

Silverleafe Capital Partners first reported a position in GILD in Q2 2018 and held it in 4 quarters. The position peaked at $2.24M in Q1 2019. 1,483 funds tracked by Wall St. Rank hold GILD as of Q2 2019.

  • Silverleafe Capital Partners reported no remaining Gilead Sciences position as of Q2 2019 after selling out during the quarter.
  • Silverleafe Capital Partners sold 34,436 Gilead Sciences shares in Q2 2019, an estimated $2.24M.
  • Silverleafe Capital Partners first reported a position in Gilead Sciences in Q2 2018 and held it in 4 quarters.
  • Silverleafe Capital Partners's Gilead Sciences position peaked at $2.24M in Q1 2019.
  • 1,483 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2019.

Based on Silverleafe Capital Partners's 13F filing for Q2 2019, filed 3 Jul 2019.